First-line anti-VEGF plus EGFR-TKI in EGFR-mutant NSCLC: adding the ARTEMIS trial to the puzzle of current evidence
Crossref DOI link: https://doi.org/10.1038/s41392-021-00813-y
Published Online: 2021-12-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Hafner, Susanne http://orcid.org/0000-0003-0663-8382
Text and Data Mining valid from 2021-12-06
Version of Record valid from 2021-12-06
Article History
Received: 6 September 2021
Revised: 7 October 2021
Accepted: 22 October 2021
First Online: 6 December 2021
Competing interests
: The author declares no competing interests.